
- /
- Supported exchanges
- / XETRA
Formycon AG (FYB XETRA) stock market data APIs
Formycon AG Financial Data Overview
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Formycon AG data using free add-ons & libraries
Get Formycon AG Fundamental Data
Formycon AG Fundamental data includes:
- Net Revenue: 60 800 K
- EBITDA: -24 446 000
- Earnings Per Share: 4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-11-13
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Formycon AG News

Those who invested in Formycon (ETR:FYB) five years ago are up 114%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you can make far more than 100% on a really good stock. Long term Formycon AG (ETR:F...


Revenues Not Telling The Story For Formycon AG (ETR:FYB)
Formycon AG's (ETR:FYB) price-to-sales (or "P/S") ratio of 13.2x might make it look like a strong sell right now compared to the Biotechs industry in Germany, where around half of the companies have P...

Those Who Purchased Formycon (ETR:FYB) Shares Three Years Ago Have A 34% Loss To Show For It
Formycon AG (ETR:FYB) shareholders should be happy to see the share price up 21% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. In fact, the sha...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.